AU2007333115B2 - Composition for treating a pulmonary hypertension - Google Patents

Composition for treating a pulmonary hypertension Download PDF

Info

Publication number
AU2007333115B2
AU2007333115B2 AU2007333115A AU2007333115A AU2007333115B2 AU 2007333115 B2 AU2007333115 B2 AU 2007333115B2 AU 2007333115 A AU2007333115 A AU 2007333115A AU 2007333115 A AU2007333115 A AU 2007333115A AU 2007333115 B2 AU2007333115 B2 AU 2007333115B2
Authority
AU
Australia
Prior art keywords
ambrisentan
subject
pah
dose
baseline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2007333115A
Other languages
English (en)
Other versions
AU2007333115A1 (en
Inventor
Christopher Dufton
Michael J. Gerber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39092031&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2007333115(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AU2007333115A1 publication Critical patent/AU2007333115A1/en
Application granted granted Critical
Publication of AU2007333115B2 publication Critical patent/AU2007333115B2/en
Assigned to GILEAD SCIENCES, INC. reassignment GILEAD SCIENCES, INC. Request for Assignment Assignors: GILEAD COLORADO, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2007333115A 2006-12-12 2007-12-11 Composition for treating a pulmonary hypertension Active AU2007333115B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86966706P 2006-12-12 2006-12-12
US60/869,667 2006-12-12
PCT/US2007/087058 WO2008073928A1 (en) 2006-12-12 2007-12-11 Composition for treating a pulmonary hypertension

Publications (2)

Publication Number Publication Date
AU2007333115A1 AU2007333115A1 (en) 2008-06-19
AU2007333115B2 true AU2007333115B2 (en) 2013-01-10

Family

ID=39092031

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007333115A Active AU2007333115B2 (en) 2006-12-12 2007-12-11 Composition for treating a pulmonary hypertension

Country Status (15)

Country Link
US (7) US20080139593A1 (enExample)
EP (2) EP2952193A1 (enExample)
JP (1) JP2010512414A (enExample)
AU (1) AU2007333115B2 (enExample)
CA (1) CA2669536C (enExample)
CY (1) CY2016017I2 (enExample)
DK (1) DK2101777T3 (enExample)
ES (1) ES2544724T3 (enExample)
HK (1) HK1218393A1 (enExample)
HU (2) HUE025355T2 (enExample)
LU (1) LU93081I2 (enExample)
PL (1) PL2101777T3 (enExample)
PT (1) PT2101777E (enExample)
SI (1) SI2101777T1 (enExample)
WO (1) WO2008073928A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2544724T3 (es) 2006-12-12 2015-09-03 Gilead Sciences, Inc. Composición para tratar una hipertensión pulmonar
CA2693400A1 (en) * 2007-07-11 2009-01-15 Lexicon Pharmaceuticals, Inc. Methods and compositions for treating pulmonary hypertension and related diseases and disorders
CA2695259C (en) 2007-07-31 2016-05-24 Gilead Colorado, Inc. Metabolites and derivatives of ambrisentan
WO2010062640A1 (en) * 2008-10-28 2010-06-03 Gilead Colorado, Inc. Methods for treating idiopathic pulmonary fibrosis and associated complications
KR20130088834A (ko) * 2010-06-30 2013-08-08 길리애드 사이언시즈, 인코포레이티드 폐 고혈압의 치료를 위한 ａ２ｂ 아데노신 수용체 길항제의 용도
ES2627944T3 (es) 2010-10-15 2017-08-01 Gilead Sciences, Inc. Composiciones y métodos de tratamiento de hipertensión pulmonar
EP2741777B1 (en) * 2011-08-12 2017-01-18 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for treatment of pulmonary hypertension
US20130225595A1 (en) * 2012-02-29 2013-08-29 Gilead Sciences, Inc. Method for treating pulmonary arterial hypertension in a patient not having idiopathic pulmonary fibrosis
US20130224306A1 (en) * 2012-02-29 2013-08-29 Gilead Sciences, Inc. Method for treating a pulmonary hypertension condition without companion diagnosis
WO2014003678A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil
WO2015193889A1 (en) * 2014-06-18 2015-12-23 Sonivie Ltd. Method for treating secondary pulmonary hypertension
US10576083B2 (en) * 2015-08-13 2020-03-03 Cipla (UK) Limited Method of treating pulmonary arterial hypertension
AU2017296040C1 (en) 2016-07-15 2023-06-22 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
SG11202000893QA (en) * 2017-08-30 2020-02-27 Bellerophon Pulse Tech Llc Use of inhaled nitric oxide for the treatment of pulmonary hypertension associated with lung disease
EA202091286A1 (ru) * 2017-12-28 2020-11-05 Беллерофон Пульс Текнолоджис Ллс Применение вдыхаемого оксида азота (ii) и кислорода для лечения легочной гипертензии
EP3965767A1 (en) * 2019-05-06 2022-03-16 Actelion Pharmaceuticals Ltd Methods for treating sarcoidosis-associated pulmonary hypertension
US11969424B2 (en) 2019-12-16 2024-04-30 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
RU2729033C1 (ru) * 2020-02-03 2020-08-03 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр кардиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ кардиологии" Минздрава России) Способ прогнозирования эффективности длительной специфической терапии у пациентов с идиопатической легочной гипертензией и неоперабельной хронической тромбоэмболической легочной гипертензией
EP4142731A1 (en) * 2020-04-28 2023-03-08 Noorik Biopharmaceuticals AG Treatment of pulmonary complications of coronavirus infections
EP3906928A1 (en) * 2020-05-06 2021-11-10 Noorik Biopharmaceuticals AG Treatment of pulmonary complications of coronavirus
CN114324900A (zh) * 2021-12-03 2022-04-12 上海市肺科医院 一种促卵泡激素的应用
US20250064799A1 (en) 2021-12-31 2025-02-27 Tenax Therapeutics, Inc. Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction
AU2024207876A1 (en) * 2023-01-09 2025-07-31 Scpharmaceuticals Inc. Methods of treatment using loop diuretics

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4325525A (en) 1980-11-13 1982-04-20 General Motors Corporation Mounting member
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
DE4313412A1 (de) 1993-04-23 1994-10-27 Basf Ag 3-(Het)aryl-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DK1174431T3 (da) 1997-11-12 2012-08-20 Bayer Pharma AG 2-phenyl-substitueret imidazo triazinon som phoshodiesterase-inhibitorer
US6821975B1 (en) 1999-08-03 2004-11-23 Lilly Icos Llc Beta-carboline drug products
WO2006007213A1 (en) * 2004-06-23 2006-01-19 Myogen, Inc. Enoximone formulations and their use in the treatment of pde-iii mediated diseases
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
TW200621261A (en) 2004-08-26 2006-07-01 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
WO2006081289A2 (en) 2005-01-25 2006-08-03 Glaxo Group Limited Antibacterial agents
SI2013208T1 (sl) * 2006-04-21 2011-09-30 Pfizer Prod Inc Piridin(3,4-b)pirazinoni
EP2091539A1 (en) * 2006-12-12 2009-08-26 Gilead Colorado, Inc. Ambrisentan combined with a renin inhibitor for hypertensive disorder
ES2544724T3 (es) * 2006-12-12 2015-09-03 Gilead Sciences, Inc. Composición para tratar una hipertensión pulmonar
CA2695259C (en) 2007-07-31 2016-05-24 Gilead Colorado, Inc. Metabolites and derivatives of ambrisentan
WO2010062640A1 (en) 2008-10-28 2010-06-03 Gilead Colorado, Inc. Methods for treating idiopathic pulmonary fibrosis and associated complications
ES2627944T3 (es) 2010-10-15 2017-08-01 Gilead Sciences, Inc. Composiciones y métodos de tratamiento de hipertensión pulmonar

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Beghetti, M. "Current treatment options in children with pulmonary arterial hypertension and experiences with oral bosentan" European Journal of Clinical Investigation (March 2006) Vol.36 Suppl 3 pages 16 to 24 *
Galie, N et al. "Ambrisentan Therapy for Pulmonary Arterial Hypertension" Journal of the American College of Cardiology (2005) Vol.46 No.3 pages 529 to 535 *

Also Published As

Publication number Publication date
US20150224100A1 (en) 2015-08-13
US8377933B2 (en) 2013-02-19
PL2101777T3 (pl) 2015-10-30
LU93081I2 (fr) 2016-07-20
CY2016017I1 (el) 2016-10-05
JP2010512414A (ja) 2010-04-22
EP2101777B1 (en) 2015-05-20
US9474752B2 (en) 2016-10-25
ES2544724T3 (es) 2015-09-03
HUS1600027I1 (hu) 2016-06-28
US20080139593A1 (en) 2008-06-12
US20110245253A1 (en) 2011-10-06
WO2008073928A1 (en) 2008-06-19
EP2101777A1 (en) 2009-09-23
CA2669536C (en) 2016-05-31
US20130116257A1 (en) 2013-05-09
US20140296244A1 (en) 2014-10-02
US9993475B2 (en) 2018-06-12
US9504685B2 (en) 2016-11-29
HUE025355T2 (en) 2016-02-29
EP2952193A1 (en) 2015-12-09
CY2016017I2 (el) 2016-10-05
HK1218393A1 (en) 2017-02-17
CA2669536A1 (en) 2008-06-19
US20100152217A1 (en) 2010-06-17
AU2007333115A1 (en) 2008-06-19
SI2101777T1 (sl) 2015-08-31
US20170136016A1 (en) 2017-05-18
PT2101777E (pt) 2015-09-18
DK2101777T3 (en) 2015-08-17

Similar Documents

Publication Publication Date Title
AU2007333115B2 (en) Composition for treating a pulmonary hypertension
US20140275094A1 (en) Method for treating pulmonary arterial hypertension in a patient not having idiopathic pulmonary fibrosis
US20240238259A1 (en) Combination therapy for pulmonary hypertension
US20140030356A1 (en) Method for treating a pulmonary hypertension condition without companion diagnosis
WO2010062640A1 (en) Methods for treating idiopathic pulmonary fibrosis and associated complications
US20080139483A1 (en) Drug combination for hypertensive disorders
RU2780758C2 (ru) Комбинированная терапия легочной гипертензии
AU3043601A (en) Use of pyrimidine endothelin antagonists in companion animals

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: GILEAD SCIENCES, INC.

Free format text: FORMER OWNER WAS: GILEAD COLORADO, INC.